Handelsbanken Fonder AB Cuts Stock Holdings in Solventum Corporation $SOLV

Handelsbanken Fonder AB trimmed its holdings in shares of Solventum Corporation (NYSE:SOLV) by 18.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 38,600 shares of the company’s stock after selling 8,700 shares during the period. Handelsbanken Fonder AB’s holdings in Solventum were worth $3,059,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after buying an additional 867,837 shares during the period. Independent Franchise Partners LLP boosted its position in Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after buying an additional 2,758,174 shares during the period. State Street Corp boosted its position in Solventum by 1.8% during the third quarter. State Street Corp now owns 6,220,271 shares of the company’s stock valued at $454,080,000 after buying an additional 112,261 shares during the period. Davis Selected Advisers boosted its position in Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after buying an additional 702,461 shares during the period. Finally, Boston Partners boosted its position in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the period.

Solventum Stock Performance

Shares of SOLV opened at $76.92 on Friday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20. The company has a 50-day simple moving average of $68.68 and a two-hundred day simple moving average of $74.77. The firm has a market capitalization of $13.32 billion, a PE ratio of 9.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.59.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the business posted $1.34 earnings per share. Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts anticipate that Solventum Corporation will post 6.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell acquired 1,475 shares of the stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.24% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SOLV shares. Stifel Nicolaus dropped their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. UBS Group lowered shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Thursday, May 14th. Rothschild & Co Redburn started coverage on shares of Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price for the company. KeyCorp increased their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.